Climb Bio, Inc.
CLYM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001768446
In the last 90 days, Climb Bio, Inc. insiders filed 0 open-market purchases and 1 sale; 108 institutions reported holding it in 13F filings for Q2 2026, worth $734.3M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:58 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 5, 2026 | Jan 10, 2025 | – | Feb 14, 2023 | Jan 18, 2022 |
| Revenue | – | $8.13M | – | – | – |
| Operating expenses | $67.9M | $82.0M | $40.3M | $45.1M | $35.7M |
| Research and development | $46.7M | $14.2M | $15.4M | $26.2M | $22.0M |
| Selling, general and administrative | $21.2M | $16.0M | $24.9M | $18.9M | $12.3M |
| Operating income | -$67.9M | -$82.0M | -$40.3M | -$45.1M | -$35.7M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$59.9M | -$73.9M | -$35.1M | -$45.2M | -$47.5M |
| EPS, basic | $-0.88 | $-1.53 | $-1.30 | $-1.72 | – |
| EPS, diluted | $-0.88 | $-1.53 | $-1.30 | $-1.72 | – |
| Weighted shares, basic | 67.8M | 48.2M | 27.0M | 26.3M | – |
| Weighted shares, diluted | 67.8M | 48.2M | 27.0M | 26.3M | 12.3M |
| Margins and growth | |||||
| Operating margin | – | -1008.6% | – | – | – |
| Net margin | – | -908.7% | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 5, 2026 | Jan 10, 2025 | – | Feb 14, 2023 | Jan 18, 2022 |
| Cash and equivalents | $35.7M | $87.2M | $93.1M | $43.6M | $46.9M |
| Short-term investments | $65.4M | $63.7M | $13.7M | $80.0M | $89.6M |
| Total current assets | $105.8M | $154.9M | $110.3M | $134.4M | $148.3M |
| Property, plant and equipment | $288.0K | – | – | – | – |
| Total assets | $167.7M | $217.2M | $110.5M | $135.0M | $173.2M |
| Accounts payable | $2.27M | $705.0K | $66.0K | $750.0K | $1.40M |
| Total current liabilities | $6.98M | $4.93M | $2.83M | $6.10M | $6.03M |
| Total liabilities | $7.27M | $5.31M | $2.87M | $6.28M | $6.04M |
| Shareholders' equity | $160.5M | $211.9M | $107.6M | $128.7M | $167.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 5, 2026 | Jan 10, 2025 | – | Feb 14, 2023 | Jan 18, 2022 |
| Operating cash flow | -$54.4M | -$15.6M | -$20.6M | -$37.4M | -$36.1M |
| Capital expenditures | $186.0K | $4.64M | – | – | – |
| Free cash flow | -$54.5M | -$20.2M | – | – | – |
| Depreciation and amortization | $97.0K | – | – | – | – |
| Stock-based compensation | $8.05M | $5.56M | $12.8M | $6.99M | $3.74M |
| Investing cash flow | $2.83M | -$121.1M | $69.0M | $34.4M | -$115.0M |
| Financing cash flow | -$21.0K | $130.7M | $841.0K | $0 | $177.2M |
| Net change in cash | -$51.5M | -$5.88M | $49.5M | -$3.34M | $26.4M |
| Ratio | |||||
| Stock-based compensation, % of revenue | – | 68.3% | – | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 30, 2026 | 58.7M | −13.9% | SEC |
| Jul 31, 2026 | 57.4M | −15.2% | SEC |
| Apr 30, 2026 | 57.3M | −15.3% | SEC |
| Feb 27, 2026 | 47.8M | −29.2% | SEC |
| Oct 31, 2025 | 68.2M | +1.4% | SEC |
| Jul 31, 2025 | 67.8M | +1.0% | SEC |
| May 9, 2025 | 67.6M | +132.3% | SEC |
| Mar 21, 2025 | 67.5M | +143.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.